Idiopathic haemochromatosis is an inherited defect of iron metabolism characterised by excessive iron absorption and deposition in the tissues leading to damage in the liver and other organs.' The nature of the fundamental metabolic abnormality remains unknown, but the liver and the gut have both been proposed as the principal site of expression of the metabolic defect. ' We recently had the opportunity to study this question when a liver was transplanted from a donor who subsequently proved to have had presymptomatic idiopathic haemochromatosis into a young woman with normal iron metabolism. We describe here the changes in iron status observed in our patient in the first 29 months after liver transplantation.
Patient, methods, and results
A 16 year old girl underwent orthotopic liver transplantation for subacute hepatic failure caused by presumed non A, non B viral hepatitis. Extensive investigation had shown no specific cause.
A liver biopsy performed on the donor organ after reperfusion showed grade 3 stainable iron within hepatocytes without significant fibrosis. Further needle biopsies in the next six weeks confirmed grade 3 or 4 hepatocyte iron staining with only a small amount of iron seen in macrophages and sinusoidal cells. The hepatic iron concentration on day 42 was 152 ,umol/g dry weight (normal , and the hepatic iron index (donor age 48 years) was 3-17. These findings suggested idiopathic haemochromatosis.
The donor was a 48 year old woman who drank virtually no alcohol and who had no history of liver disease, anaemia, or blood transfusions. The donor's HLA haplotype included the A3 allele, which is known to be strongly associated with idiopathic haemochromatosis.' In addition, two siblings of the donor were found to have significantly raised serum ferritin concentrations and on liver biopsy showed greatly increased iron stores, confirming the diagnosis of idiopathic haemochromatosis in the donor family.
Findings on the recipient's iron studies before operation were as follows: iron 33 ,umol/l (normal 13-30), total iron binding capacity 38 ,umol/l (45-73) , and serum ferritin 106 ,ug/l (9-190). The serum ferritin concentration was measured regularly as a guide to iron stores, and by the 42nd day after transplantation, it had risen to 1585,ug/l. It subsequently fell progressively, until by 29 months it was normal (figure). At this point the serum iron concentration had fallen to 14 pmol/l. Four estimates of dry weight liver iron showed a progressive reduction from 152,mol/g immediately after transplantation to normal (30 ,umol/g) at 29 months. The iron indices retumed to normal in the absence of abnormal blood losses.
Comment
Intuitively it seems reasonable to seek the expression of the metabolic defect of idiopathic haemochromatosis in the gut since increased assimilation of dietary iron is the major abnormality leading to increased body iron stores.' In patients with idiopathic haemochromatosis a larger than normal proportion of the iron taken up by the enterocyte is transferred into the body.7 Further support for the epithelial cell as the site of the defect comes from immunohistochemical findings; these show a failure of downregulation of the enterocyte transferrin receptor by iron overload in patients with idiopathic haemochromatosis.3
Some evidence exists for hepatic control of iron metabolism, however, and hence of tissue iron accumulation in haemochromatosis. Patients with idiopathic haemochromatosis who have been "deironed" have a significantly higher hepatic iron uptake after intravenous infusion than controls.4 The influence of the liver on iron absorption has been shown in a study in rats,5 in which the transplanting of iron loaded livers into normal animals significantly reduced iron absorption in the graft recipients.
In our study, in which a liver from a patient with idiopathic haemochromatosis was transplanted into a recipient with normal iron metabolism, liver iron concentrations and serum ferritin concentrations retumed to normal in the absence of any abnormal source of iron loss. This case provides strong evidence against a primary hepatic defect in idiopathic haemochromatosis.
We thank Dr J W Halliday for performing liver iron estimations and Drs S Fairley and M Malone for assisting with the investigation of the donor family. 
Subjects, methods, and results
Two groups of subjects were studied. The first was nine otherwise healthy patients (including two postmenopausal women) with uncomplicated gall stone disease; they had a mean (SEM) age of 51 (5) (see table) . In contrast, lipoprotein (a) levels increased after treatment in all but three subjects.
Comments
In contrast to oestrogen treatment,5 and contrary to our original hypothesis, growth hormone administration had opposing effects on low density lipoprotein cholesterol and lipoprotein (a) concentrations. The difference appeared to be more pronounced in the older subjects (the patients with gall stones).
The results of these two open studies underline the complexity of lipoprotein (a) metabolism.4 Clearly the twofold to threefold upregulation of hepatic low density lipoprotein receptors that occurs during growth hormone treatment3 is not sufficient adequately to clear lipoprotein (a). Thus, it seems reasonable to assume that an enhanced hepatic production of lipoproteins and lipoprotein (a) occurs, possibly as a consequence of the increased lipolytic activity induced by growth hormone. Furthermore, the fact that insulinlike growth factor-I levels are increased during growth hormone treatment but reduced during oestrogen therapy may indicate that this factor has a role in the regulation of lipoprotein (a) metabolism. Other metabolic adaptations to the hormonal treatment, such as hyperinsulinaemia, may also be important. The increase in lipoprotein (a) concentration is a clinically undesirable effect of growth hormone treatment. Although only long term controlled studies can evaluate the overall advantages and disadvantages of growth hormone treatment in various conditions, these results call for caution in considering growth hormone treatment in patients other than children with growth hormone deficiency. When I went to the secondary school bigger boys hit me for wearing specs and broke them. I knew it cost seven and sixpence to get them mended and I went home contrite, but there was not a lot I could do about it. We were a soccer school. If I took my specs off I couldn't see the ball. If I kept them on they got broken.
In my 50s I was promoted to bifocals. In my mid-60s I found that I could no longer see to thread a trout fly on to a cast unless I took my specs off. I took them off and dropped them in the river. Much, much more than seven and sixpence.
"You've got presbyopia," the optician told me." I knew. "It's something elderly people get," the optician told me. I knew that, too. Now I had to take my specs off to see properly to cut my nails or to read small print, but when I took them off I couldn't look for them until I had them on. I tried hanging them round my neck but forgot I had done so. Sometimes I pushed them up over my head where I never thought to look.
I feel rather like a mixed infant once again.-DENIS CASHMAN is a retired generalpractitioner in Cuflercoats
